Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma

Aim: We sought to investigate the efficacy of adoptive transfer of TILs plus anti-PD1 therapy in metastatic osteosarcoma patients. Materials and methods: A total of 30 patients received anti-PD1 therapy (Group 1) while 30 patients were subjected to TILs plus anti-PD1 therapy (Group 2). Progression-f...

Full description

Bibliographic Details
Main Authors:	Chao Wang, Ming Li, Rong Wei, Junlong Wu
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Journal of Bone Oncology
Subjects:	Metastatic osteosarcoma TILs Immunotherapy Prognostic factor PD1 Adverse effects
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212137420300877

Similar Items

Comprehensive Analysis Reveals Prognostic and Therapeutic Immunity-Related Biomarkers for Pediatric Metastatic Osteosarcoma
by: Jin Yuan, et al.
Published: (2024-01-01)

Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome
by: Alini Trujillo-Paolillo, et al.
Published: (2023-03-01)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01)

Osteosarcoma with Telangiectatic Features Metastatic to the Small Bowel
by: Geoffrey G. Herndon, et al.
Published: (2021-06-01)

Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC)
by: Mayada Saad Farrag, et al.
Published: (2021-07-01)

A Review of T-Cell Related Therapy for Osteosarcoma
by: Kazushige Yoshida, et al.
Published: (2020-07-01)

Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients
by: Xuanhong He, et al.
Published: (2022-07-01)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
by: Christopher Aled Chamberlain, et al.
Published: (2022-03-01)

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
by: Yueshui Zhao, et al.
Published: (2022-08-01)

The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma
by: Fan M, et al.
Published: (2021-01-01)

Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma
by: Longqing Li, et al.
Published: (2022-05-01)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
by: Miaomiao Gou, et al.
Published: (2023-05-01)

Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective
by: Giuseppe Angelico, et al.
Published: (2023-09-01)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
by: Jiaqiang Wang, et al.
Published: (2023-11-01)

Novel Immunotherapies for Osteosarcoma
by: Yubao Lu, et al.
Published: (2022-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1<sup>+</sup> Subsets in Mouse Immunocompetent Models
by: Alvaro Morales-Molina, et al.
Published: (2020-07-01)

Novel therapies in platinumrefractory metastatic germ cell tumor: a case report with a focus on a PD-1 inhibitor
by: Kah Poh Loh, et al.
Published: (2017-07-01)

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
by: Wang T, et al.
Published: (2022-10-01)

Osteosarcoma metastasis to the orbit presenting as severe proptosis following trivial trauma
by: Amit Agrawal
Published: (2014-01-01)

Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
by: Nicoletta Nastasi, et al.
Published: (2023-09-01)

Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model
by: Mariangela Garofalo, et al.
Published: (2023-11-01)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
by: Binhao Shi, et al.
Published: (2023-06-01)

Systematic Review of Recurrent Osteosarcoma Systemic Therapy
by: Ioanna Gazouli, et al.
Published: (2021-04-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
by: Stijn Jeroen De Keukeleire, et al.
Published: (2022-05-01)

Takk til fagfeller
by: Ingri Løkholm Ramberg, et al.
Published: (2020-12-01)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
by: Melissa L. Bastacky, et al.
Published: (2021-11-01)

Correlation Between PD-1/CTLA-4 Expressions with C linicopathological Features and Prognosis of Osteosarcoma Patients
by: YAN Guangning, et al.
Published: (2023-01-01)

Recurrent spontaneous pneumothoraxes as a complication of osteosarcoma metastases: a case report
by: Mark Kleedehn, MD, et al.
Published: (2021-11-01)

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
by: William C. Kisseberth, et al.
Published: (2021-06-01)

Immunotherapy for osteosarcoma
by: Kenichiro Yahiro, et al.
Published: (2021-05-01)

The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
by: Lucy Davis, et al.
Published: (2023-09-01)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
by: Lu Chen, et al.
Published: (2019-12-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
by: Rozala Arko, et al.
Published: (2022-07-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
by: Amrendra Kumar, et al.
Published: (2021-06-01)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
by: Le Yan, et al.
Published: (2023-01-01)

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy
by: Andrea Katharina Lindner, et al.
Published: (2023-06-01)

PD-L1 in Combination with CD8+TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma
by: Zhou Z, et al.
Published: (2020-12-01)